Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sofinnova Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
2,015,644Website Global Rank
8,743Website Monthly Traffic
Twitter Followers
Description
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2020 | EnginZyme | Series A | 6.9M |
| 7/2019 | Abivax | Post-IPO Equity | 13.5M |
| 3/2010 | Omthera Pharmaceuticals | Series A | 6.5M |
| 10/2002 | Cobion | Venture Round | 5.9M |
| 4/2013 | MedDay | Series A | 10.5M |
| 8/2006 | Ablynx | Series C | 50M |
| 1/2016 | ENYO Pharma | Series A | 23.9M |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 3/2005 | Sequoia Pharmaceuticals | Series B | 22M |
| 8/2000 | BioSpace | Series B | 10M |
| 9/2010 | Bee Ware | Series B | 5.6M |
| 5/2005 | Bee Ware | Series A | 3.8M |
| 3/2008 | Filao | Venture Round | 0 |
| 12/2007 | Ascendis Pharma | Series A | 25.7M |
| 12/2019 | GenSight Biologics | Post-IPO Debt | 16.6M |
| 4/2022 | LimFlow SA | Series D | 0 |
| 4/2014 | ProQR Therapeutics | Series A | 57.9M |
| 3/2005 | Filao | Venture Round | 4.6M |
| 7/2020 | Enthera | Series A | 0 |
| 1/2006 | Blyk | Series A | 35.4M |
| 3/2016 | CelluComp | Venture Round | 5.3M |
| 3/2018 | SafeHeal | Series A | 7.4M |
| 11/2021 | Synthace | Series C | 35M |
| 1/2007 | Stentys | Seed Round | - |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 9/2013 | Synthace | Seed Round | 2.1M |
| 1/2010 | BioAmber | Series A | 0 |
| 10/2022 | Mablink Bioscience | Series A | 30.1M |
| 7/2021 | protera | Series A | 0 |
| 3/2009 | Neosens | Series B | 5.3M |
| 2/2008 | Neosens | Venture Round | 3.7M |
| 5/2004 | Addex Therapeutics | Series B | 0 |
| 11/2013 | Pixium Vision | Series A | 20.3M |
| 5/2009 | MXP4 | Series B | 2.7M |
| 1/2004 | Infra Worlds | Series A | 1.7M |
| 3/2007 | MXP4 | Series A | 6.5M |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 2/2019 | GenSight Biologics | Post-IPO Equity | 9.1M |
| 5/2023 | BrightHeart | Seed Round | 2.1M |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 1/2009 | DBV Technologies | Series B | 7.8M |
| 4/2020 | RefleXion Medical | Series D | 0 |
| 7/2009 | EOS (Ethical Oncology Science) | Series A | 17M |
| 1/2008 | CrestaTech | Series A | 5M |
| 1/2005 | CrestaTech | Seed Round | 1.5M |
| 1/2006 | DBV Technologies | Venture Round | 15.1M |
| 1/2013 | ProQR Therapeutics | Seed Round | - |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 4/2016 | MedDay | Series B | 0 |
| 3/2008 | Laszlo Systems | Series C | 14.6M |
| 4/2006 | Endoart | Series C | 0 |
| 3/2018 | Micropep Technologies | Series A | 5M |
| 2/2003 | Avaki | Series A | 4.2M |
| 12/2021 | DMC Biotechnologies | Series B | 0 |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 12/2019 | DMC Biotechnologies | Series A | 0 |
| 11/2011 | NuCana BioMed | Series A | 10.5M |
| 12/2022 | EnginZyme | Series B | 22.3M |
| 10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
| 7/2019 | AblaCare | Series A | 11.2M |
| 5/2022 | GFBiochemicals | Series A | 0 |
| 12/2018 | Shockwave Medical | Series D | 0 |
| 2/2017 | Zyl | Venture Round | - |
| 3/2017 | Biotalys | Series B | 0 |
| 12/2013 | Crescendo Biologics | Series A | 28.5M |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 1/2002 | Innate Pharma | Series B | 17.8M |
| 4/2004 | Ablynx | Series B | 30M |
| 7/2007 | Inside Secure | Series B | 0 |
| 3/2000 | Innate Pharma | Series A | 4.4M |
| 3/2023 | Noema Pharma | Series B | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 12/2013 | Green Biologics | Series B | 0 |
| 5/2015 | Twenga | Series A | 11M |
| 1/2009 | Revolt Technology | Series B | 13.1M |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 7/2006 | Accent | Venture Round | 13.3M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 10/2006 | Domain Therapeutics | Series C | 10.4M |
| 11/2003 | Esmertec AG | Series C | 0 |
| 6/2005 | Revolt Technology | Series A | 8.5M |
| 6/2021 | Borea Therapeutics | Seed Round | - |
| 10/1998 | BoostWorks | Series A | 3M |
| 11/2021 | GlycoEra | Series A | 0 |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 4/2008 | Qosmos | Series C | 10.8M |
| 1/2004 | Intransa | Series C | 8M |
| 5/2010 | Crocus Technology | Series C | 0 |
| 1/2005 | VoluBill | Series C | 0 |
| 4/2018 | LimFlow SA | Series C | 33.4M |
| 2/2002 | Tak Imaging | Series B | 9.5M |
| 9/2019 | Inotrem | Series B | 43.1M |
| 10/2004 | Sensitive Object | Series A | 2.5M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 8/2022 | F2G | Private Equity Round | 0 |
| 7/2007 | GlycoVaxyn | Series A | 9.5M |
| 7/2005 | Filao | Venture Round | 0 |
| 1/2019 | HighLife | Series B | 36M |
| 9/2007 | Purple Labs | Series A | 12.7M |
| 4/2002 | Esmertec AG | Venture Round | 8.8M |
| 7/2021 | protera | Series A | 0 |
| 11/2002 | PhyFlex Networks | Series B | 0 |
| 6/2019 | Comet Therapeutics | Series A | 28.5M |
| 7/2021 | Micropep Technologies | Series A | 10.1M |
| 4/2013 | Aledia | Series A | 12.8M |
| 6/2022 | Micropep Technologies | Series A | 0 |
| 2/2002 | Domain Therapeutics | Series A | 2.6M |
| 7/2019 | Biotalys | Series C | 0 |
| 10/2010 | ASSIA | Series D | 20.8M |
| 1/2007 | Movetis | Series A | 63.8M |
| 6/2010 | QuesCom | Venture Round | 0 |
| 4/2020 | Pi-Cardia | Venture Round | 27M |
| 7/2020 | Pixium Vision | Post-IPO Equity | 8.3M |
| 7/2002 | Addex Therapeutics | Series A | 9.9M |
| 1/2003 | Intransa | Series B | 6M |
| 9/2017 | DNA Script | Series A | 13.2M |
| 9/2017 | Synthace | Series A | 9.9M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 10/2018 | Sitryx Therapeutics | Series A | 30M |
| 3/2020 | Redx Pharma | Post-IPO Equity | 33.6M |
| 1/2004 | Tak Imaging | Series C | 16.3M |
| 9/2002 | Ablynx | Series A | 4.9M |
| 4/2005 | Tak Imaging | Series C | 10M |
| 11/2005 | Fovea Pharmaceuticals | Series A | 24.2M |
| 3/2004 | UPEK | Series A | 20M |
| 7/1999 | BoostWorks | Series B | 7M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 2/2013 | MetGen | Venture Round | 2.9M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 11/2006 | Abionyx Pharma | Series B | 53.5M |
| 3/2008 | Mobile Digital Media | Venture Round | 0 |
| 7/2019 | Comet Biorefining | Venture Round | - |
| 6/2020 | Protera | Series A | 5.6M |
| 1/2015 | Green Biologics | Equity | 42M |
| 8/2004 | Intransa | Series D | 24M |
| 1/2005 | Biolipox | Series C | 41M |
| 12/2007 | Streamezzo | Series C | 22M |
| 2/2002 | Intransa | Venture Round | 10M |
| 4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
| 2/2015 | Synthace | Venture Round | 3.4M |
| 11/2006 | CoreValve | Venture Round | 20M |
| 5/2010 | Noxxon Pharma | Series D | 40.7M |
| 10/2009 | Crescendo Biologics | Seed Round | 0 |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 5/2004 | Domain Therapeutics | Series B | 19.1M |
| 1/2018 | Aledia | Series C | 0 |
| 3/2014 | Inotrem | Series A | 25.1M |
| 5/2007 | Noxxon Pharma | Series C | 50.2M |
| 11/2018 | InCarda Therapeutics | Series B | 42M |
| 4/2018 | Erydel | Series B | 32.4M |
| 9/2020 | POLYNEURON | Series A | 15.4M |
| 5/2014 | Avantium | Series G | 0 |
| 7/2006 | GlycoVaxyn | Seed Round | - |
| 4/2014 | RefleXion Medical | Series A | 11.6M |
| 11/2014 | myTomorrows | Venture Round | 5.6M |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
| 3/2009 | GlycoVaxyn | Series B | 21.4M |
| 2/2012 | BioAmber | Series C | 0 |
| 10/2017 | HighLife | Series A | 14.3M |
| 7/2018 | HotSpot Therapeutics | Series A | 45M |
| 4/2014 | Crescendo Biologics | Series A | 3.3M |
| 11/2019 | TISSIUM | Series B | 43.2M |
| 5/2018 | Biosyntia | Series A | 4.7M |
| 10/2011 | Creabilis | Series B | 20M |
| 4/2015 | ReCor Medical | Series D | 15M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 6/2009 | blueKiwi software | Series B | 0 |
| 4/2006 | Varioptic | Series C | 0 |
| 6/2015 | Aledia | Series B | 0 |
| 7/2019 | Microphyt | Venture Round | 31.9M |
| 6/2018 | Castle Biosciences | Venture Round | 0 |
| 1/2008 | TAK imaging | Series C | 16.2M |
| 9/2002 | EnvoyWorldWide | Series C | 4.5M |
| 12/2021 | EndoRon Medical | Seed Round | 5M |
| 6/2016 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series B | 33M |
| 1/2003 | Biolipox | Series B | 21M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 3/2008 | Stentys | Series A | 18M |
| 4/2014 | NuCana | Series B | 0 |
| 1/2007 | blueKiwi software | Series A | 5.3M |
| 2/2019 | AFYREN | Venture Round | 23.8M |
| 6/2018 | NodThera | Series A | 40M |
| 10/2021 | Leucid Bio | Series A | 15.9M |
| 2/2018 | Mainstay Medical | Post-IPO Equity | 37.5M |
| 2/2021 | Mainstay Medical | Private Equity Round | 0 |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 1/2011 | DBV Technologies | Series C | 25.5M |
| 5/2019 | CinCor Pharma | Series A | 50M |
| 3/2004 | Varioptic | Series B | 12.2M |
| 10/2003 | Cotherix | Series C | 55M |
| 9/2004 | Innate Pharma | Series C | 0 |
| 5/2009 | Streamezzo | Series D | 5.5M |
| 7/2010 | Abionyx Pharma | Series C | 0 |
| 11/2016 | Shockwave Medical | Series C | 45M |
| 4/2018 | EnobraQ | Seed Round | 3.6M |
| 7/2021 | Comet Biorefining | Series C | 0 |
| 10/2016 | MD Start | Venture Round | 0 |
| 3/2017 | Comet Biorefining | Venture Round | - |
| 7/2022 | Biosyntia | Series B | 11.7M |
| 4/2016 | RefleXion Medical | Series B | 52M |
| 4/2018 | RefleXion Medical | Series C | 100M |
| 2/2016 | Corvidia | Series A | 26M |
| 1/2007 | Sequoia Pharmaceuticals | Series C | 35M |
| 4/2006 | Streamezzo | Series B | 0 |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 6/2021 | Alia Therapeutics | Seed Round | - |
| 6/2013 | MetGen | Series A | - |
| 6/2016 | DNA Script | Seed Round | 2.8M |
| 3/2007 | CoreValve | Series C | 33M |
| 8/2005 | Abionyx Pharma | Series A | 30.5M |
| 5/2015 | Shockwave Medical | Series B | 40M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 12/2020 | Noema Pharma | Series A | 60M |
| 1/2008 | Inside Secure | Series C | 0 |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 4/2005 | Laszlo Systems | Series B | 6.3M |
| 9/2007 | VoluBill | Series D | 0 |
| 1/2017 | myTomorrows | Venture Round | 10.6M |
| 3/2011 | Omthera Pharmaceuticals | Series B | 33.9M |
| 6/2020 | NodThera | Series B | 55M |
| 10/2021 | IOmx Therapeutics | Series B | 0 |
| 4/2018 | Corvidia | Series B | 60M |
| 3/2017 | Breath Therapeutics | Series A | 45.9M |
| 5/2020 | CorVent Medical | Seed Round | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 2/2010 | Odoo | Series A | 4.1M |
| 4/2020 | Pyrowave | Series B | - |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 1/2021 | Corwave | Series C | 43.2M |
| 11/2013 | CelluComp | Seed Round | 3.9M |
| 7/2018 | Enthera | Seed Round | 4.7M |
| 6/2021 | AAVantgarde Bio | Seed Round | - |
| 9/2006 | Qosmos | Series B | 4.1M |
| 2/2022 | Elicit Plant | Series A | 18.3M |
| 1/2014 | Shockwave Medical | Series A | 12.5M |
| 6/2022 | Moon Surgical | Series A | 31.3M |
| 4/2013 | Auris Medical | Series C | 51M |
| 2/2015 | Comet Biorefining | Venture Round | - |
| 1/2003 | Varioptic | Series A | 2.1M |
| 1/2002 | EnvoyWorldWide | Series B | 8M |
| 2/2013 | Entourage Medical Technologies | Venture Round | 3.3M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 3/2017 | HotSpot Therapeutics | Seed Round | - |
| 11/2020 | Myricx Pharma | Seed Round | 5.9M |
| 3/2019 | POLYNEURON | Series A | 22.6M |
| 12/2009 | Sensitive Object | Series B | 6M |
| 9/2019 | Inventiva Pharma | Post-IPO Equity | 681.2k |
| 10/2021 | Sphere Fluidics | Venture Round | 41.4M |
| 11/2022 | Microphyt | Series B | 0 |
| 4/2020 | Genespire | Series A | 17.4M |
| 11/2011 | NuCana | Series A | 0 |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 6/2008 | Creabilis | Series A | 31.4M |
| 9/2006 | Oxxius | Series B | 10M |
| 4/2005 | TAK imaging | Series C | 10M |
| 6/2005 | Endotis | Series A | 4.9M |
| 9/2016 | Delinia | Series A | 35M |
| 5/2014 | Odoo | Series B | 10M |
| 8/2008 | mydeco | Series A | 14.5M |
| 10/2006 | Wyplay | Series A | 5.1M |
| 5/2005 | Sefas Innovation | Venture Round | 3.8M |
| 1/2022 | SafeHeal | Venture Round | 0 |
| 9/2004 | Oxxius | Series A | 2.9M |
| 3/2016 | TISSIUM | Series A | 25.5M |
| 6/2007 | PregLem | Series A | 26M |
| 2/2020 | Inventiva Pharma | Post-IPO Equity | 16.4M |
| 4/2020 | Epsilen Bio | Seed Round | - |
| 6/2019 | AFYX Therapeutics | Debt Financing | 13M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 7/2010 | Mainstay Medical | Series A | 6.1M |
| 7/2007 | Diatos | Series D | 12.8M |
| 11/2016 | Corwave | Series B | 17.1M |
| 11/2021 | Home Biosciences | Seed | 15M |
| 4/2022 | Prometheus Materials | Series A | 8M |
| 12/2007 | PregLem | Series B | 32.2M |
| 5/2020 | PinCell s.r.l. | Seed Round | 1.6M |
| 8/2021 | TISSIUM | Series C | 59.1M |
| 5/2023 | BrightHeart | Seed Round | 0 |
| 5/2023 | TISSIUM | Series D | 0 |
| 5/2023 | Moon Surgical | Series B | 0 |
| 5/2023 | Werewool | Seed Round | 0 |
| 4/2023 | Alia Therapeutics | Seed Round | 0 |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 3/2023 | deepc | Series A | 0 |
| 3/2023 | Kiro | Series A | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
